Your browser doesn't support javascript.
loading
Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance.
Hill, Deanna D; Kramer, Jennifer R; Chaffin, Kassie R; Mast, T Christopher; Robertson, Michael N; Kanwal, Fasiha; Haber, Barbara A.
Afiliação
  • Hill DD; Merck & Co., Inc., Rahway, NJ, United States. Electronic address: deanna.hill@merck.com.
  • Kramer JR; Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, TX, United States; Department of Medicine, Baylor College of Medicine, Houston, TX, United States.
  • Chaffin KR; Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, TX, United States.
  • Mast TC; Merck & Co., Inc., Rahway, NJ, United States.
  • Robertson MN; Merck & Co., Inc., Rahway, NJ, United States.
  • Kanwal F; Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, TX, United States; Department of Medicine, Baylor College of Medicine, Houston, TX, United States.
  • Haber BA; Merck & Co., Inc., Rahway, NJ, United States.
Ann Hepatol ; 28(2): 100899, 2023.
Article em En | MEDLINE | ID: mdl-36632975
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite C / Hepatite C Crônica Tipo de estudo: Diagnostic_studies / Observational_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite C / Hepatite C Crônica Tipo de estudo: Diagnostic_studies / Observational_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article